Santhera's Duchenne effort gets a boost on positive PhIIa for alternative steroid vamorolone — though there's a lot left to prove
Months after Santhera got its hands on a second Duchenne muscular dystrophy drug, the Swiss company is getting an early look at how it improves …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
